| Identification | Back Directory | [Name]
Edoxaban-d6 | [CAS]
1304701-57-2 | [Synonyms]
Edoxaban-d6
[2H6]-Edoxaban
Edoxaban hydrochloride salt
N-[(1S,2R,4S)-4-[bis(trideuteriomethyl)carbamoyl]-2-[(5-methyl-6,7-dihydro-4H-[1,3]thiazolo[5,4-c]pyridine-2-carbonyl)amino]cyclohexyl]-N'-(5-chloropyridin-2-yl)oxamide | [Molecular Formula]
C24H30ClN7O4S | [MDL Number]
MFCD32661438 | [MOL File]
1304701-57-2.mol | [Molecular Weight]
548.06 |
| Chemical Properties | Back Directory | [Melting point ]
>205°C (dec.) | [storage temp. ]
Hygroscopic, Refrigerator, under inert atmosphere | [solubility ]
Chloroform (Slightly), Dichloromethane (Slightly) | [form ]
Solid | [color ]
Pale Orange to Pale Red | [Stability:]
Hygroscopic |
| Hazard Information | Back Directory | [Description]
Edoxaban-d6 is intended for use as an internal standard for the quantification of edoxaban by GC- or LC-MS. Edoxaban is an orally bioavailable and potent inhibitor of factor Xa (Kis = 0.561 and 0.903 nM for free and complexed human factor Xa, respectively). It is >10,000-fold selective for factor Xa over thrombin, FVIIa/sTF, FXIa, tPA, aPC, trypsin, plasmin, and chymotrypsin. Edoxaban prolongs prothrombin, activated partial thromboplastin, and thrombin clotting times in a concentration-dependent manner ex vivo in human plasma. Oral administration of edoxaban (0.5-12.5 mg/kg) reduces thrombus formation and prolongs prothrombin time in a dose-dependent manner in rat and rabbit models of venous stasis thrombosis. It also reduces thrombus formation in a rat model of platinum wire-induced venous thrombosis. Formulations containing edoxaban have been used to prevent stroke in patients with atrial fibrillation. | [Uses]
Edoxaban-d6 is the isotope labelled analog of Edoxaban (E555520); an anticoagulant drug which acts as a direct factor Xa inhibitor. |
|
| Company Name: |
Energy Chemical
|
| Tel: |
021-58432009 400-005-6266 |
| Website: |
http://www.energy-chemical.com |
|